In this pooled analysis of the three GetGoal trials, addition of lixisenatide to basal insulin improved HbA1c and reduced postprandial glucose, regardless of baseline fasting plasma glucose, with no increased risk of symptomatic hypoglycemia while mitigating weight gain in patients with T2D. This evidence concerns the gene INS and type 2 diabetes mellitus.